Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics reported positive initial clinical data for AlloNK® (AB-101) in refractory rheumatoid arthritis (RA) and other autoimmune diseases, with a 71% ACR50 response rate in RA patients with at least six months of follow-up. The treatment regimen demonstrated tolerability results supportive of outpatient administration in community rheumatology settings, with no CRS, ICANS, or treatment discontinuations related to AlloNK reported. Artiva achieved FDA alignment on a single Phase 3 registrational trial design in refractory RA, with plans to initiate the trial in the second half of 2026.
Key figures
- Eps Beat
- 0
- Revenue
- 0
- Revenue Yoy
- 0
- Net loss
- 23516000
- Other income net
- 914000
- Comprehensive loss
- 23637000
- Net loss per share
- -0.95
- Cash and cash equivalents
- 86782000
- Research and development expenses
- 19312000
- General and administrative expenses
- 5118000
- Weighted average common shares outstanding
- 24678420
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.